

# Overexpression of *TRMT12* may independently predict poor overall survival in patients with head and neck squamous cell carcinoma

This article was published in the following Dove Press journal:  
*OncoTargets and Therapy*

Kai Wang<sup>1</sup>  
Mengmeng Zheng<sup>1</sup>  
Yuan Ren<sup>1,2</sup>

<sup>1</sup>Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, People's Republic of China; <sup>2</sup>Department of Otorhinolaryngology Head and Neck Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, Zhejiang, People's Republic of China

**Purpose:** The *TRMT12* is a novel oncogene involved in breast cancer. However, the association between *TRMT12* and head and neck squamous cell carcinoma (HNSCC) remains unclear.

**Materials and methods:** The levels of *TRMT12* mRNA in HNSCC and normal tissues were analyzed using data from the Cancer Genome Atlas-HNSC. The expression of *TRMT12* was also determined using quantitative real-time polymerase chain reaction in 165 paired HNSCC and adjacent normal tissues, which were used as the validation cohort.

**Results:** *TRMT12* expression was significantly increased in HNSCC tissues versus normal tissues. High *TRMT12* expression was significantly associated with human papillomavirus infection, perineural invasion, tumor invasion, lymphatic metastasis, and clinical stage. Moreover, elevated *TRMT12* expression was correlated with unfavorable overall survival (hazard ratio [HR]: 1.711, 95% confidence interval [CI]: 1.141–2.567,  $P=0.009$ ) and recurrence-free survival (HR: 1.648, 95% CI: 1.060–2.563,  $P=0.027$ ) in HNSCC patients.

**Conclusion:** *TRMT12* was significantly upregulated in HNSCC tissues, which may be attributed to both genetic and epigenetic alterations. Increased *TRMT12* expression may be involved in the progression and metastasis of HNSCC, and serve as an independent biomarker of poor prognosis in HNSCC with respect to overall survival and recurrence-free survival.

**Keywords:** tRNA methyltransferase 12 homolog, bioinformatics, head and neck squamous cell carcinoma, prognosis, survival

## Introduction

Head and neck cancer is the sixth most common type of cancer and fifth leading cause of cancer-related death worldwide. The highest prevalence is reported in south-central Asia, northern America, and central Europe.<sup>1</sup> Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 90% of all head and neck cancer cases. According to the International Agency for Research on Cancer, the global annual incidence of HNSCC is more than 1 million cases.<sup>2</sup> Although excessive use of tobacco and alcohol are the primary etiological factors of HNSCC, there is increasing molecular and epidemiological evidence supporting the causal role of human papillomavirus (HPV) infection in HNSCC, especially for oropharyngeal cancer.<sup>3</sup> Despite great achievements based on manifold interdisciplinary treatment approaches, the survival rate of HNSCC patients has not improved significantly in the

Correspondence: Yuan Ren  
Department of Otorhinolaryngology  
Head and Neck Surgery, Ningbo Medical  
Center Lihuili Eastern Hospital, 1111  
Jiangnan Road, Ningbo 315000, Zhejiang,  
People's Republic of China  
Tel +86 1 596 893 2131  
Email ren8302@sina.com

previous decades.<sup>3</sup> Notably, the 5-year survival rate of patients with HNSCC is <50%.<sup>1</sup> Traditional prognostic factors, such as tumor–node–metastasis stage, histological grade, positive surgical margins, and perineural invasion, are currently used to predict the outcome of HNSCC.<sup>4</sup> However, these factors are inadequate to predict the prognosis of individual patients, due to the heterogeneous molecular mechanisms and tumor behaviors linked to HNSCC.<sup>5</sup> Therefore, identification of biomarkers associated with clinical outcomes of HNSCC may facilitate proper therapeutic decision-making and improve prognosis. Nevertheless, thus far, research studies have not successfully identified clinically useful biomarkers of prognosis in HNSCC.

The *TRMT12* gene is the human homolog to the yeast *TRM12* gene,<sup>6</sup> and is a tRNA methyltransferase catalyzing the third step in the biochemical pathway to form wybutosine. The latter is a hypermodified guanosine at the 3-prime position adjacent to the anticodon of phenylalanine tRNA, stabilizing codon–anticodon interactions during decoding on the ribosome.<sup>7</sup> A recent report revealed that overexpression of *TRMT12* in both breast cancer tissues and cell lines may lead to disruption of the wybutosine biochemical pathway. This results in hypomodified phenylalanine tRNA which may ultimately lead to translational errors in cancer cells.<sup>8</sup> However, the expression profile of *TRMT12* and its role in other types of cancer (including HNSCC) remain unclear.

The Cancer Genome Atlas (TCGA) Data Portal – established by the National Cancer Institute's Center for Cancer Genomics and the National Human Genome Research Institute – contains DNA, RNA, protein, and survival data related to various types of cancer, including HNSCC (<http://cancergenome.nih.gov/>).<sup>9</sup> In the present study, the expression profile, clinical significance, prognostic value in terms of overall survival (OS) and recurrence-free survival (RFS), and mechanism of dysregulation of *TRMT12* in HNSCC were investigated through data mining from the TCGA.

## Materials and methods

### Data mining – HNSCC

The level-3 data of primary HNSCC in the TCGA cohort (Project Id: TCGA-HNSC) were obtained using the University of California Santa Cruz Xena browser (<https://xenabrowser.net/>). Via this approach, *TRMT12* RNA-sequencing data, *TRMT12* Illumina Human Methylation 450K data,

and details of the clinicopathological characteristics of patients (ie, sample type, age at initial pathologic diagnosis, gender, alcohol history, tobacco smoking history, anatomic neoplasm subdivision, HPV status by p16 testing, neoplasm histologic grade, pathologic T, pathologic N, pathological stage, OS status, and OS time) were collected and downloaded for secondary analysis. The RNA-sequencing data was normalized based on the values of reads per kilobase of transcript per million mapped reads. A total of 517 HNSCC patients with integrated *TRMT12* expression and OS data were divided into high and low *TRMT12* expression groups. This classification was performed according to the maximum Youden index based on receiver operating characteristic curves for the detection of death in HNSCC patients. Accordingly, there were 339 and 178 patients in the high and low *TRMT12* expression groups, respectively. The mean  $\beta$  values of five CpG probes (cg11829072, cg25375711, cg26547947, cg22853986, and cg00846483) mapping 200 bp downstream of the transcription start sites of *TRMT12* were defined as the level of methylation of the *TRMT12* promoter. *TRMT12* genetic alterations reported in TCGA-HNSC were examined using the cBioPortal for Cancer Genomics (<http://www.cbioportal.org/>).<sup>10</sup>

### Collection of tissue specimens

To validate the findings of the bioinformatics analysis, 165 HNSCC tissues with adjacent non-tumorous tissues were collected from the Ningbo Medical Centre Lihuili Hospital (Ningbo, China) and the Affiliated Tumor Hospital of Xiangya Medical School (Changsha, China) between February 2004 and November 2018. None of the patients received treatment prior to surgical excision. The final diagnosis was histopathologically confirmed by two pathologists according to the clinical practice guidelines established by the National Comprehensive Cancer Network. Tumors were determined according to the seventh edition of the tumor–node–metastasis staging system produced by the International Union Against Cancer. All specimens were preserved in RNA-fixer Reagent (Biotek, Beijing, China) at –80 °C. The clinical and survival data of all patients were collected. The median follow-up period was 24 months (interquartile range: 14–43 months). During the follow-up, 13 patients were lost and 70 patients expired.

This study was approved by the Human Research Ethics Committee of Ningbo Medical Centre Lihuili Hospital (Ningbo, China) and the Affiliated Tumor Hospital of Xiangya Medical School (Changsha, China). All patients provided written informed consent prior to their participation in this study.

## Extraction of total RNA and quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted from the frozen tissues using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the instructions provided by the manufacturer. Reverse transcription and qRT-PCR was performed as previously described.<sup>11</sup> In the present study, the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase was used as an endogenous control to normalize the cycle threshold (*Ct*) value. The primers were synthesized by Huada Biotech (Shen Zhen, China) and their sequences were as follows: *TRMT12*, forward: 5'-GGGAGAGACGCTTCCAGAG-3' and reverse: 5'-GAGCTGCGTGAGCATAACAGG-3'; and glyceraldehyde 3-phosphate dehydrogenase, forward: 5'-CCATGGAGAAGGCTGGGG-3' and reverse: 5'-CAAAGTTGTCATGGATGACC-3'. The PCR conditions were as follows: 95 °C for 10 min, 45 amplification cycles at 95 °C for 20 s, 55 °C for 35 s, and 70 °C for 30 s. The expression of *TRMT12* was calculated using the  $\Delta C_t$  method. All experiments were performed in triplicate.

## Statistical analysis


All statistical analyses were performed using the IBM SPSS, version 20.0 (IBM Corp., Armonk, NY, USA) and R 3.5.1 software (<https://www.r-project.org/>), which were also used to generate figures. Independent Student's *t*-tests were applied to identify correlations between *TRMT12* expression and clinical features of HNSCC. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of *TRMT12* for

HNSCC. OS and RFS were compared between the high and low *TRMT12* expression groups using Kaplan–Meier curves, and log-rank tests were performed to evaluate the difference between the survival curves. A univariate cox proportional hazards model was utilized to determine *TRMT12* expression and established important clinicopathologic features associated with OS or RFS. Hazard ratios (HR) with 95% confidence intervals (CI) were obtained for each variable. A multivariate cox proportional hazards model was utilized to verify the correlations between *TRMT12* expression and survival along with significant clinical features identified in the univariate analysis. The correlation between *TRMT12* expression and methylation was tested using the Spearman's rank correlation coefficient. A  $P < 0.05$  denoted statistical significance.

## Results

### TRMT12 expression is upregulated in HNSCC versus normal head and neck tissue

Using mRNA-sequencing data from the Xena browser, we reviewed the expression of *TRMT12* in 520 HNSCC tissues and 44 head and neck normal tissues in TCGA-HNSC. By comparing with the normal tissue, we found that the expression of *TRMT12* was significantly upregulated in HNSCC patients in the TCGA database (Figure 1A and B,  $P = 3.79E-10$ ). The qRT-PCR analysis of the 165 paired HNSCC samples confirmed that the expression of *TRMT12* was significantly upregulated in HNSCC tissues versus adjacent normal tissues ( $P = 3.85E-30$ , Figure 1C).



**Figure 1** *TRMT12* expression levels were significantly elevated in HNSCC tissues versus adjacent normal tissues. Heatmap (A) and plot (B) showing increased *TRMT12* expression in HNSCC tissues (N=520) versus normal tissues (N=44) in the TCGA database. (C) *TRMT12* expression levels were significantly higher in HNSCC tissues (N=165) versus paired non-tumor tissues in our validation cohort.

**Abbreviation:** N, sample number.

## Correlation between TRMT12 expression and clinicopathological features of HNSCC patients

In addition, we analyzed the relationship between *TRMT12* expression and clinicopathological features of HNSCC patients in the TCGA database. *TRMT12* expression was up-regulated in HPV-negative patients versus HPV-positive patients ( $8.426 \pm 0.528$  vs  $7.686 \pm 1.277$ , respectively,  $P=0.001$ , Table 1). Perineural invasion-positive patients presented with significantly higher levels of *TRMT12* expression versus perineural invasion-negative patients ( $8.487 \pm 0.752$  vs  $8.231 \pm 0.861$ , respectively,  $P=0.003$ , Table 1). In addition, the expression of *TRMT12* was higher in those with an advanced T stage (T1/2:  $8.203 \pm 0.807$  vs T3/4:  $8.421 \pm 0.800$ ,  $P=0.004$ , Table 1). Moreover, *TRMT12* expression increased in patients with lymph node metastasis versus those without lymph node metastasis (N1–N3:  $8.451 \pm 0.809$  vs N0:  $8.201 \pm 0.785$ , respectively,  $P=0.002$ , Table 1). Significantly elevated levels of *TRMT12* expression were found in patients with an advanced clinical stage (I + II:  $8.073 \pm 0.852$  vs III + IV:  $8.409 \pm 0.783$ ,  $P=2.28E-04$ , Table 1). Subsequently, by analyzing the clinicopathological characteristics of 165 patients in our validation cohort, we observed that the differences in *TRMT12* expression were related to history of alcohol consumption ( $P=0.015$ , Table 2), tumor invasion ( $P=0.005$ , Table 2), lymphatic metastasis ( $P=0.026$ , Table 2), and clinical stage ( $P=0.001$ , Table 2). However, *TRMT12* expression was not related to other clinicopathological features.

## The diagnostic value of TRMT12 for HNSCC

We assessed the diagnostic value of *TRMT12* for HNSCC using ROC curve analysis, which is a synthesized index that reflects the accuracy of diagnostic test. An area under the ROC curve (AUC) close to 1.0 signifies that the test has almost perfect diagnostic value. The maximum Youden index was used as a cut-off point. We found *TRMT12* expression yielded an AUC of 0.760 (95% CI: 0.712–0.808), a sensitivity of 57.7% and a specificity of 97.7% (Figure 2).

## High TRMT12 expression is an independent risk factor of OS in HNSCC patients

A total of 517 HNSCC patients, with complete *TRMT12* expression and OS data in the TCGA-HNSC, were enrolled to investigate the prognostic value of *TRMT12*. Based on the best performing threshold, the Kaplan–

**Table 1** Association between *TRMT12* expression and clinicopathological characteristics of HNSCC patients in the TCGA database

Characteristics	N	Mean ± SD	P-value
Gender			
Female	136	8.282±0.692	0.573
Male	384	8.327±0.847	
Age			
<60 years	233	8.238±0.919	0.056
≥60 years	286	8.379±0.703	
Smoking history			
No	117	8.250±0.747	0.362
Yes	391	8.328±0.828	
Alcohol history			
No	162	8.236±0.788	0.105
Yes	347	8.360±0.810	
Histologic grade			
G1+2	366	8.368±0.782	0.054
G3+4	132	8.198±0.888	
Tumor site			
Oral cavity\Pharynx	404	8.309±0.835	0.737
Larynx	116	8.338±0.712	
HPV status			
Negative	73	8.426±0.528	0.001
Positive	38	7.686±1.277	
Perineural invasion			
Negative	193	8.231±0.861	0.003
Positive	169	8.487±0.752	
Pathologic tumor			
Tis/T1/T2	185	8.203±0.807	0.004
T3/T4	273	8.421±0.800	
Pathologic nodal			
No	176	8.201±0.785	0.002
Yes	244	8.451±0.809	
Pathologic stage			
I + II	101	8.073±0.852	2.28E-04
III + IV	347	8.409±0.783	

Abbreviation: N, sample number.


Meier analysis showed that high *TRMT12* expression was associated with worse OS (log-rank  $P=2.26E-05$ , Figure 3A). In addition, 152 HNSCC patients with

**Table 2** Association between *TRMT12* expression and clinicopathological characteristics of HNSCC patients in the validation cohort

Characteristics	N	Mean $\pm$ SD	P-value
Gender			
Female	37	6.630 $\pm$ 2.339	0.859
Male	128	6.550 $\pm$ 2.426	
Age			
<60 years	90	6.885 $\pm$ 2.179	0.066
$\geq$ 60 years	75	6.186 $\pm$ 2.604	
Smoking history			
No	57	6.700 $\pm$ 2.327	0.615
Yes	108	6.500 $\pm$ 2.446	
Alcohol history			
No	107	6.903 $\pm$ 2.244	0.015
Yes	58	5.953 $\pm$ 2.571	
Histologic grade			
Well/moderately	115	6.690 $\pm$ 2.357	0.323
Poorly	50	6.287 $\pm$ 2.496	
Tumor site			
Oral cavity/Pharynx	131	6.484 $\pm$ 2.391	0.382
Larynx	34	6.889 $\pm$ 2.439	
Tumor Invasion			
Tis/T1/T2	63	7.195 $\pm$ 1.959	0.005
T3/T4	102	6.180 $\pm$ 2.568	
Lymphatic metastasis			
No	69	7.057 $\pm$ 2.224	0.026
Yes	96	6.216 $\pm$ 2.470	
Clinical stage			
I + II	80	7.226 $\pm$ 2.157	0.001
III + IV	85	5.948 $\pm$ 2.463	


**Abbreviation:** N, sample number.

sufficient OS data were analyzed to confirm this finding. The Kaplan–Meier analysis confirmed that high *TRMT12* expression was associated with shorter OS (log-rank  $P=0.01$ , Figure 3B) in our validation cohort. The subgroup analyses were performed according to *TRMT12* significantly associated clinicopathological features. By generating Kaplan–Meier curves of OS, we showed that high *TRMT12* expression significantly affected the OS in the following HNSCC patients: HPV-negative (log-rank  $P=7.8E-04$ , Figure 4A and B), perineural invasion-

**Figure 2** The receiver operating characteristic (ROC) curve. The arrow points to the intercept.

negative (log-rank  $P=0.015$ , Figure 4C and D), lymph node metastatic (log-rank  $P=0.002$ , Figure 4E and F), and advanced clinical stage (log-rank  $P=0.003$ , Figure 4G and H). However, subgroup analysis indicated that high *TRMT12* expression was associated with significantly worse OS in both early T stage (log-rank  $P=0.023$ , Figure 4I) and advanced T stage (log-rank  $P=0.002$ , Figure 4J) patients. Subsequently, a Cox proportional hazards model was performed to assess the independent risk factors of OS in HNSCC patients. In the univariate model, age (HR: 1.318, 95% CI: 1.003–1.731,  $P=0.047$ ), gender (HR: 1.349, 95% CI: 1.014–1.796,  $P=0.047$ ), perineural invasion (HR: 2.135, 95% CI: 1.516–3.007,  $P=1.42E-05$ ), pathologic stage (HR: 1.754, 95% CI: 1.203–2.558,  $P=0.004$ ), and *TRMT12* expression (HR: 1.910, 95% CI: 1.409–2.591,  $P=3.11E-05$ ) were significantly associated with OS. After adjustment of the prognostic risk factors, the subsequent multivariate analysis confirmed that high *TRMT12* expression (HR: 1.711, 95% CI: 1.141–2.567,  $P=0.009$ ), perineural invasion positive (HR: 1.984, 95% CI: 1.387–2.838,  $P=1.76E-04$ ), and advanced pathologic stage (HR: 1.830, 95% CI: 1.104–3.035,  $P=0.019$ ) were independent prognostic factors of poor OS in HNSCC patients. All independent risk factors and their HR with 95% CI are listed in Table 3.






**Figure 3** Kaplan–Meier analysis of 517 HNSCC patients (A) in the TCGA database and 152 HNSCC patients (B) in our validation cohort with recorded *TRMT12* expression and OS data. High *TRMT12* expression was significantly associated with worse OS in HNSCC patients in both the TCGA and validation cohorts.

## High *TRMT12* expression independently predicted poor RFS among HNSCC patients

Using the TCGA dataset that contained follow-up data of HNSCC recurrence in 425 patients, we produced Kaplan–Meier curves to determine whether *TRMT12* expression was

associated with recurrence in such patients. As shown in Figure 5, the log-rank test of the Kaplan–Meier curves in TCGA-HNSC indicated that high *TRMT12* expression was markedly related to worse RFS versus low *TRMT12* expression ( $P=0.005$ ). The univariate Cox proportional hazards




**Figure 4** Subgroup analysis of Kaplan–Meier plotter. (A, B): High expression of *TRMT12* was associated with worse OS in HPV-negative patients but not in HPV-positive patients. (C, D): *TRMT12* high expression was associated with shorter OS in perineural invasion-negative patients but not in perineural invasion-positive patients. (E, F): Increased *TRMT12* expression was correlated with poor OS in lymph node-positive patients but not in lymph node-negative patients. (G, H): Elevated *TRMT12* expression was linked to shorter OS in patients with advanced-stage disease but not in patients with early-stage disease. (I, J): Elevated *TRMT12* expression was correlated with poor OS in both T1/2 and T3/4 patients.

**Table 3** Univariate and multivariate analyses of overall survival in HNSCC patients

Characteristics	Univariate analysis			Multivariate analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age (<60 years vs ≥60 years)	1.318	1.003–1.731	0.047	1.057	0.746–1.498	0.755
Gender (Female vs male)	1.349	1.014–1.796	0.040	1.132	0.767–1.672	0.532
Smoking history (Yes vs No)	1.123	0.803–1.572	0.498	–	–	–
Alcohol history (Yes vs No)	0.942	0.709–1.252	0.680	–	–	–
Histologic grade (G3/4 vs G1/2)	0.867	0.637–1.180	0.363	–	–	–
Perineural invasion (Yes vs No)	2.135	1.516–3.007	1.42E–05	1.984	1.387–2.838	1.76E–04
Pathologic stage (III + IV vs I + II)	1.754	1.203–2.558	0.004	1.830	1.104–3.035	0.019
TRMT12 expression (High vs Low)	1.910	1.409–2.591	3.11E–05	1.711	1.141–2.567	0.009

**Abbreviations:** HR, hazard ratio; CI, confidence interval.

**Figure 5** Kaplan–Meier analysis of 435 HNSCC patients with recorded *TRMT12* expression and RFS data. High *TRMT12* expression was significantly associated with worse RFS in HNSCC patients.

analysis showed that alcohol consumption (HR: 1.809, 95% CI: 1.130–2.896,  $P=0.014$ ), advanced stage (HR: 2.302, 95% CI: 1.249–4.242,  $P=0.007$ ), and high *TRMT12* expression (HR: 1.864, 95% CI: 1.255–2.769,  $P=0.002$ ) were associated

with worse RFS in HNSCC patients (Table 4). Subsequently, the multivariate Cox proportional hazards analysis confirmed that advanced stage (HR: 2.036, 95% CI: 1.095–3.785,  $P=0.025$ ) and high *TRMT12* expression (HR: 1.648, 95% CI: 1.060–2.563,  $P=0.027$ ) were independent prognostic factors of poor RFS (Table 4).


## TRMT12 upregulation was related to DNA amplification and promoter hypomethylation in HNSCC

To further investigate the mechanism of *TRMT12* dysregulation in HNSCC, we examined its genetic and epigenetic alterations in TCGA-HNSC using the sequencing and copy number alterations data of 504 HNSCC patients in TCGA-HNSC. Our analysis revealed that 53 HNSCC patients (11%) had genetic alterations of *TRMT12*, with amplification being the predominant type of alteration (Figure 6A). Further plot analysis using the cBio-Portal for Cancer Genomics showed that amplification was associated with increased *TRMT12* expression in HNSCC (Figure 6B). Subsequently, we analyzed the expression of *TRMT12* and the methylation status of its promoter using data


**Table 4** Univariate and multivariate analyses of recurrence-free survival in HNSCC patients

Characteristics	Univariate analysis			Multivariate analysis		
	HR	95% CI	P-value	HR	95% CI	P-value
Age (<60 years vs ≥60 years)	1.291	0.878–1.899	0.194			
Gender (Female vs male)	0.894	0.571–1.401	0.626			
Smoking history (Yes vs No)	0.973	0.626–1.513	0.904			
Alcohol history (Yes vs No)	1.809	1.130–2.896	0.014	1.463	0.891–2.403	0.132
Histologic grade (G3/4 vs G1/2)	0.821	0.526–1.281	0.384			
Perineural invasion (Yes vs No)	1.576	0.990–2.511	0.055			
Pathologic stage (III + IV vs I + II)	2.302	1.249–4.242	0.007	2.036	1.095–3.785	0.025
TRMT12 expression (High vs Low)	1.864	1.255–2.769	0.002	1.648	1.060–2.563	0.027

**Abbreviations:** HR, hazard ratio; CI, confidence interval.



**Figure 6** Association between genetic alteration of *TRMT12* and its expression in HNSCC tissues. **(A)** Sequencing and copy number alterations of *TRMT12* in 504 HNSCC cases. *TRMT12* was altered in 11% (53/504) of sequenced HNSCC patients. **(B)** Box plots showed that DNA amplification was associated with elevated *TRMT12* expression in HNSCC.



**Figure 7** Correlation between *TRMT12* expression and the methylation status of its promoter in HNSCC tissues. Heatmap **(A)** and plot **(B)** showing that *TRMT12* expression was negatively correlated with the methylation status of its promoter in HNSCC.



from 520 HNSCC patients. We observed a strong negative correlation (Pearson's  $r = -0.639$ ,  $P=6.16E-61$ ) between *TRMT12* expression and promoter methylation (Figure 7).

## Discussion

Progress achieved in the fields of genetics and molecular biology has promoted the rapid development of personalized treatment and management of cancer.<sup>5</sup> the identification of crucial biomarkers may contribute to improved individualized treatment and prognosis of HNSCC.<sup>12</sup> Rodriguez was the first to report the high expression of *TRMT12* in breast cancer.<sup>8</sup> However, few studies have investigated *TRMT12* expression in other cancers, including HNSCC. In the present study, using bioinformatics analysis based on TCGA-HNSC data and our validation patient cohort, we initially determined the expression profile of *TRMT12* in HNSCC. The results showed that HNSCC tissues exhibited significantly elevated *TRMT12* expression compared with normal head and neck tissues, indicating its potential function as an oncogene in this setting.

Furthermore, we assessed the clinical significance of *TRMT12* expression in HNSCC using the TCGA cohort and validation cohort. Increasing evidence has shown that HPV infection is an independent pathogenic factor of HNSCC.<sup>13,14</sup> HPV-positive and -negative HNSCC patients differ in terms of the molecular mechanisms underlying their respective oncogenic processes and clinical outcomes.<sup>15,16</sup> HPV-positive patients are more susceptible to radiation and chemotherapy with a favorable prognosis versus HPV-negative patients.<sup>17</sup> In the TCGA cohort, we observed that *TRMT12* expression was significantly elevated in HNSCC patients without HPV infection versus those with HPV infection. This finding indicated that *TRMT12* may play an important role in HNSCC carcinogenesis, specifically in HPV-negative patients. Additionally, data obtained from the TCGA showed that high *TRMT12* expression was related to perineural invasion, tumor invasion, lymphatic metastasis, and advanced pathologic stage. This is consistent with the findings observed in the validation cohort for the expression of *TRMT12* in HNSCC patients, suggesting that *TRMT12* may be involved in the progression and metastasis of this type of cancer.

In the present study, we also constructed ROC curves and calculated the AUC to determine the diagnostic value of *TRMT12* expression for HNSCC. Although the AUC and sensitivity were not encouraging, the specificity was close to 1.0, signifying that *TRMT12* expression might have excellent diagnostic accuracy for HNSCC combining with other high sensitivity biomarkers.

Although surgical resection remains the mainstay treatment for HNSCC, adjuvant therapy (ie, immunotherapy, radiotherapy, and chemotherapy) have achieved great progress in recent years, especially in patients with advanced HNSCC.<sup>5,18</sup> Due to tumor heterogeneity and resistance to chemotherapy, the prediction of high-risk HNSCC patients and application of precision therapy remain challenges for both clinicians and pathologists.<sup>19</sup> Therefore, the use of reliable predictive biomarkers is urgently required to guide treatment selection in HNSCC patients. In the present study, by generating Kaplan–Meier curves of OS, we observed that high *TRMT12* expression was significantly associated with unfavorable OS in both the TCGA and validation cohorts. Subsequent univariate and multivariate cox proportional hazards analyses showed that high *TRMT12* expression was an independent prognostic factor of poor OS. These findings imply that *TRMT12* upregulation may serve as a predictive biomarker of patient prognosis. Interestingly, subgroup analyses showed that high expression of *TRMT12* was associated with worse OS in the following patients: HPV-negative, perineural invasion-negative, lymph node metastatic, and advanced clinical stage. These findings demonstrated the specific prognostic role of *TRMT12* expression and its potential contribution to the development of precision therapy against HNSCC.

Despite aggressive, site-specific, multimodal therapy, a considerable proportion of HNSCC patients develop locoregional recurrence, which adversely impacts treatment and survival. Hence, recurrence is an important factor in the choice of treatment.<sup>12,20</sup> In this study, we also investigated the association of *TRMT12* expression with recurrence in HNSCC patients using the TCGA cohort. The Kaplan–Meier analysis showed that elevated *TRMT12* expression was significantly correlated with unfavorable RFS. Subsequently, univariate and multivariate Cox proportional hazards analyses confirmed that high *TRMT12* expression was an independent factor of unfavorable RFS in HNSCC patients. This evidence indicated that *TRMT12* upregulation may be useful in treatment stratification and surveillance for recurrence of HNSCC.

Subsequently, the potential underlying mechanisms of *TRMT12* upregulation in HNSCC were investigated. DNA amplification is an important form of copy number variation, which refers to a form of genomic structural variation, which results in abnormal gene copy numbers.<sup>21</sup> Moreover, DNA amplification is an important influential factor for the expression of both protein-coding and non-coding genes, affecting the activity of various signaling pathways in numerous types of cancer.<sup>22,23</sup> In this study, we performed

an analysis of *TRMT12* DNA amplification and expression data in TCGA-HNSC using the cBio-Portal. We found that DNA amplification was associated with elevated *TRMT12* expression. We further examined the potential association between the methylation status of the *TRMT12* promoter and its mRNA expression. As a major form of epigenetic modification, aberrant methylation in the promoter region is associated with gene expression in numerous types of cancer,<sup>24,25</sup> including HNSCC.<sup>26</sup> The results revealed that promoter hypomethylation was significantly associated with increased *TRMT12* expression. These findings indicated that both genetic and epigenetic alterations contribute to the dysregulation of *TRMT12* in HNSCC.

## Conclusion

The present findings demonstrated that *TRMT12* was significantly upregulated in HNSCC tissues, and this upregulation may be attributed to both genetic and epigenetic alterations. The increased *TRMT12* expression may be involved in the progression and metastasis of HNSCC. Additionally, elevated *TRMT12* expression was an independent biomarker of poor prognosis in HNSCC with respect to OS and RFS. However, the mechanism through which *TRMT12* functions as an oncogene in HNSCC remains to be determined.

## Acknowledgment

This research was supported by grants from the Ningbo Health Branding Subject Fund (PPXK2018-02).

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Shield KD, Ferlay J, Jemal A, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. *CA Cancer J Clin*. 2017;67(1):51–64. doi:10.3322/caac.21384
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.21492
- Gooi Z, Chan JY, Fakhry C. The epidemiology of the human papillomavirus related to oropharyngeal head and neck cancer. *Laryngoscope*. 2016;126(4):894–900. doi:10.1002/lary.25767
- Huang SH, O'Sullivan B. Overview of the 8th edition TNM classification for head and neck cancer. *Curr Treat Options Oncol*. 2017;18(7):40. doi:10.1007/s11864-017-0484-y
- Kaidar-Person O, Gil Z, Billan S. Precision medicine in head and neck cancer. *Drug Resist Updat*. 2018;40:13–16. doi:10.1016/j.drup.2018.09.001
- Kalhor HR, Penjwini M, Clarke S. A novel methyltransferase required for the formation of the hypermodified nucleoside wybutosine in eucaryotic tRNA. *Biochem Biophys Res Commun*. 2005;334(2):433–440. doi:10.1016/j.bbrc.2005.06.111
- Noma A, Suzuki T. Ribonucleome analysis identified enzyme genes responsible for wybutosine synthesis. *Nucleic Acids Symp Ser (Oxf)*. 2006;(50):65–66.
- Rodriguez V, Chen Y, Elkahoul A, Dutra A, Pak E, Chandrasekharappa S. Chromosome 8 BAC array comparative genomic hybridization and expression analysis identify amplification and overexpression of *TRMT12* in breast cancer. *Genes Chromosomes Cancer*. 2007;46(7):694–707. doi:10.1002/gcc.20454
- Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. *Nat Genet*. 2013;45(10):1113–1120. doi:10.1038/ng.2764
- Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-0095
- Shen Z, Hao W, Zhou C, et al. Long non-coding RNA AC026166.2-001 inhibits cell proliferation and migration in laryngeal squamous cell carcinoma by regulating the miR-24-3p/p27 axis. *Sci Rep*. 2018;8(1):3375. doi:10.1038/s41598-018-21659-5
- Sacco AG, Cohen EE. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. *J Clin Oncol*. 2015;33(29):3305–3313. doi:10.1200/JCO.2015.62.0963
- Bussu F, Ragin C, Boscolo-Rizzo P, et al. HPV as a marker for molecular characterization in head and neck oncology: looking for a standardization of clinical use and of detection method(s) in clinical practice. *Head Neck*. 2019;41(4):1104–1111. doi:10.1002/hed.25591
- Tsai SC, Huang JY, Lin C, Liaw YP, Lin FC. The association between human papillomavirus infection and head and neck cancer: a population-based cohort study. *Medicine (Baltimore)*. 2019;98(7):e14436. doi:10.1097/MD.00000000000014436
- Koneva LA, Zhang Y, Virani S, et al. HPV integration in HNSCC correlates with survival outcomes, immune response signatures, and candidate drivers. *Mol Cancer Res*. 2018;16(1):90–102. doi:10.1158/1541-7786.MCR-17-0153
- Saada-Bouaid E, Peyrade F, Guigay J. Molecular genetics of head and neck squamous cell carcinoma. *Curr Opin Oncol*. 2019;31(3):131–137. doi:10.1097/CCO.0000000000000536
- Brakenhoff RH, Wagner S, Klussmann JP. Molecular patterns and biology of HPV-associated HNSCC. *Recent Results Cancer Res*. 2017;206:37–56. doi:10.1007/978-3-319-43580-0\_3
- Schuler PJ, Laban S, Doescher J, Bullinger L, Hoffmann TK. Novel treatment options in head and neck cancer. *Oncol Res Treat*. 2017;40(6):342–346. doi:10.1159/000477254
- Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the Phase Ib KEYNOTE-012 expansion cohort. *J Clin Oncol*. 2016;34(32):3838–3845. doi:10.1200/JCO.2016.68.1478
- Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. *Mayo Clin Proc*. 2016;91(3):386–396. doi:10.1016/j.mayocp.2015.12.017
- Liang L, Fang JY, Xu J. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. *Oncogene*. 2016;35(12):1475–1482. doi:10.1038/ncr.2015.209
- Liu J, Wu Y, Wang Q, Liu X, Liao X, Pan J. Bioinformatic analysis of PFN2 dysregulation and its prognostic value in head and neck squamous carcinoma. *Future Oncol*. 2018;14(5):449–459. doi:10.2217/fon-2017-0348
- Tian C, Zhou S, Yi C. High NUP43 expression might independently predict poor overall survival in luminal A and in HER2+ breast cancer. *Future Oncol*. 2018;14(15):1431–1442. doi:10.2217/fon-2017-0690
- Heng J, Zhang F, Guo X, et al. Integrated analysis of promoter methylation and expression of telomere related genes in breast cancer. *Oncotarget*. 2017;8(15):25442–25454. doi:10.18632/oncotarget.16036

25. Zhou C, Li J, Li Q. CDKN2A methylation in esophageal cancer: a meta-analysis. *Oncotarget*. 2017;8(30):50071–50083. doi:10.18632/oncotarget.18412
26. Zhou C, Ye M, Ni S, et al. DNA methylation biomarkers for head and neck squamous cell carcinoma. *Epigenetics*. 2018;13(4):398–409. doi:10.1080/15592294.2018.1465790

### OncoTargets and Therapy

Dovepress

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>